Gilead Sciences Profile

74.17
USD 0.90  1.23%
25%
37%

Payment of 894 shares by Metza Kristen of Gilead Sciences subject to Rule 16b-3

Gilead Sciences insider trading alert for payment of common stock by Metza Kristen, SVP Human Resources, on October 16, 2018. This event was filed by Gilead Sciences Inc with SEC on 2009-03-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in California U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 96.15 B. Gilead Sciences conducts business under Healthcare sector and is part of Biotechnology industry. This company has 1.3 B outstanding shares of which 13.22 M shares are currently shorted by private and institutional investors with about 2.26 trading days to cover. GILEAD SCIENCES currently holds about 27.1 B in cash with 8.31 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.91.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Gilead Sciences Target Price Odds Analysis

Odds Below 74.17HorizonTargetOdds Above 74.17
19.43%30 days 74.17 80.25%
Based on normal probability distribution, the odds of Gilead Sciences to move above current price in 30 days from now is about 80.25% (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Gilead Sciences Top Holders

Gilead Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Gilead Sciences Key Fundamentals

Gilead Sciences Against Markets

Gilead Sciences Current Ratings

Gilead Sciences 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for Gilead Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 10000 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classification
Currently Active Investing Idea
Macroaxis Index
  Macroaxis Index
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCalifornia U.S.A
Business Address333 Lakeside Drive
Foreign Associates
ExchangeBATS Exchange
CIK Number0000882095
ISINUS3755581036
CUSIP375558103
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.gilead.com
Phone650 574 3000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestSeptember 28, 2018

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Gilead Sciences Directors

Gilead Sciences Corporate Directors

Gayle Wilson Independent Director
Jacqueline Barton Director
John Madigan Independent Director
Please also check Risk vs Return Analysis. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com